131 related articles for article (PubMed ID: 16226275)
21. Structural stability of human protein tyrosine phosphatase ρ catalytic domain: effect of point mutations.
Pasquo A; Consalvi V; Knapp S; Alfano I; Ardini M; Stefanini S; Chiaraluce R
PLoS One; 2012; 7(2):e32555. PubMed ID: 22389709
[TBL] [Abstract][Full Text] [Related]
22. Activation of Engineered Protein Tyrosine Phosphatases with the Biarsenical Compound AsCy3-EDT
Chan WC; Knowlton GS; Bishop AC
Chembiochem; 2017 Oct; 18(19):1950-1958. PubMed ID: 28745017
[TBL] [Abstract][Full Text] [Related]
23. Allostery in Protein Tyrosine Phosphatases is Enabled by Divergent Dynamics.
Welsh CL; Madan LK
J Chem Inf Model; 2024 Feb; 64(4):1331-1346. PubMed ID: 38346324
[TBL] [Abstract][Full Text] [Related]
24. High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.
Lountos GT; Raran-Kurussi S; Zhao BM; Dyas BK; Burke TR; Ulrich RG; Waugh DS
Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):1015-1026. PubMed ID: 30289412
[TBL] [Abstract][Full Text] [Related]
25. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain.
Hill JM; Vaidyanathan H; Ramos JW; Ginsberg MH; Werner MH
EMBO J; 2002 Dec; 21(23):6494-504. PubMed ID: 12456656
[TBL] [Abstract][Full Text] [Related]
26. Structure of human dual-specificity phosphatase 7, a potential cancer drug target.
Lountos GT; Austin BP; Tropea JE; Waugh DS
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):650-6. PubMed ID: 26057789
[TBL] [Abstract][Full Text] [Related]
27. Mapping the Chemical Space of Active-Site Targeted Covalent Ligands for Protein Tyrosine Phosphatases.
Hong SH; Xi SY; Johns AC; Tang LC; Li A; Hum MN; Chartier CA; Jovanovic M; Shah NH
Chembiochem; 2023 May; 24(10):e202200706. PubMed ID: 36893077
[TBL] [Abstract][Full Text] [Related]
28. The receptor PTPRU is a redox sensitive pseudophosphatase.
Hay IM; Fearnley GW; Rios P; Köhn M; Sharpe HJ; Deane JE
Nat Commun; 2020 Jun; 11(1):3219. PubMed ID: 32591542
[TBL] [Abstract][Full Text] [Related]
29. Regulation of lymphoid tyrosine phosphatase activity: inhibition of the catalytic domain by the proximal interdomain.
Liu Y; Stanford SM; Jog SP; Fiorillo E; Orrú V; Comai L; Bottini N
Biochemistry; 2009 Aug; 48(31):7525-32. PubMed ID: 19586056
[TBL] [Abstract][Full Text] [Related]
30. Sequence - dynamics - function relationships in protein tyrosine phosphatases.
Crean RM; Corbella M; Calixto AR; Hengge AC; Kamerlin SCL
QRB Discov; 2024; 5():e4. PubMed ID: 38689874
[TBL] [Abstract][Full Text] [Related]
31. Single Residue on the WPD-Loop Affects the pH Dependency of Catalysis in Protein Tyrosine Phosphatases.
Shen R; Crean RM; Johnson SJ; Kamerlin SCL; Hengge AC
JACS Au; 2021 May; 1(5):646-659. PubMed ID: 34308419
[TBL] [Abstract][Full Text] [Related]
32. Enzyme Mechanistic Studies of NMA1982, a Protein Tyrosine Phosphatase and Potential Virulence Factor in Neisseria meningitidis.
Wu S; Coureuil M; Nassif X; Tautz L
Res Sq; 2023 Aug; ():. PubMed ID: 37693380
[TBL] [Abstract][Full Text] [Related]
33. NMA1982 is a Novel Phosphatase and Potential Virulence Factor in
Wu S; Coureuil M; Nassif X; Tautz L
bioRxiv; 2023 May; ():. PubMed ID: 37292688
[TBL] [Abstract][Full Text] [Related]
34. Single Ion Pair Is Essential for Stabilizing SHP2's Open Conformation.
Kim SH; Bulos ML; Adams JA; Yun BK; Bishop AC
Biochemistry; 2024 Feb; 63(3):273-281. PubMed ID: 38251939
[TBL] [Abstract][Full Text] [Related]
35. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases.
Eswaran J; von Kries JP; Marsden B; Longman E; Debreczeni JE; Ugochukwu E; Turnbull A; Lee WH; Knapp S; Barr AJ
Biochem J; 2006 May; 395(3):483-91. PubMed ID: 16441242
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis of PTPN21 reveals a dominant-negative effect of the FERM domain on its phosphatase activity.
Chen L; Qian Z; Zheng Y; Zhang J; Sun J; Zhou C; Xiao H
Sci Adv; 2024 Mar; 10(9):eadi7404. PubMed ID: 38416831
[TBL] [Abstract][Full Text] [Related]
37. Protein Tyrosine Phosphatases: A new paradigm in an old signaling system?
Welsh CL; Pandey P; Ahuja LG
Adv Cancer Res; 2021; 152():263-303. PubMed ID: 34353440
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of
Dingwoke EJ; Adamude FA; Chukwuocha CE; Ambi AA; Nwobodo NN; Sallau AB; Nzelibe HC
J Exp Pharmacol; 2019; 11():135-148. PubMed ID: 31908547
[TBL] [Abstract][Full Text] [Related]
39. Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase.
Stanford SM; Aleshin AE; Zhang V; Ardecky RJ; Hedrick MP; Zou J; Ganji SR; Bliss MR; Yamamoto F; Bobkov AA; Kiselar J; Liu Y; Cadwell GW; Khare S; Yu J; Barquilla A; Chung TDY; Mustelin T; Schenk S; Bankston LA; Liddington RC; Pinkerton AB; Bottini N
Nat Chem Biol; 2017 Jun; 13(6):624-632. PubMed ID: 28346406
[TBL] [Abstract][Full Text] [Related]
40. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships.
Zeke A; Misheva M; Reményi A; Bogoyevitch MA
Microbiol Mol Biol Rev; 2016 Sep; 80(3):793-835. PubMed ID: 27466283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
